{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:02:25Z","timestamp":1790888545862,"version":"4.1.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>IKZF1 deletions (\u0394IKZF1) are commonly detected in B-precursor acute lymphoblastic leukemia (ALL; B-ALL) and are widely assumed to have a significant impact on outcome. We compared the ability of multiplex ligand-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) to detect \u0394IKZF1 and to determine the impact on event-free survival of patients with precursor B-ALL aged 23 to 65 years recruited to the completed trial UKALL14 (ISRCTN 66541317). From 655 recruits with BCR-ABL1+ and BCR-ABL1\u2212 B-ALL, all available diagnostic DNA samples (76% of the recruited population) were screened by multiplex end point PCR covering 4 deletions: dominant-negative (DN) \u03944-7 or the loss of function \u03942-7, \u03944-8, and \u03942-8 (n = 498), MLPA (n = 436), or by both (n\u00a0= 420). Although patients with BCR-ABL1\u2212 \u0394IKZF1 were more likely to have minimal residual disease at the end of induction, we did not find any impact of \u0394IKZF1 (including subgroup analysis for DN or loss-of-function lesions) or the IKZF1plus genotype on event-free, overall survival, or relapse risk by univariable or multivariable analyses. Consistent with the technical approach, MLPA not only detected a wider range of deletions than PCR but also failed to detect some PCR-detected lesions. The main difference between our study and others reporting an association between \u0394IKZF1 and outcome is the older age of participants in our population. The impact of \u0394IKZF1 in ALL may be less marked in an older population of patients. Our study underscores the need for analyses in large, harmonized data sets. This trial was registered at www.clinicaltrials.gov as #NCT01085617.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004430","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:54:27Z","timestamp":1630670067000},"page":"3322-3332","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["<i>IKZF1<\/i> alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial"],"prefix":"10.1182","volume":"5","author":[{"given":"Rachel J.","family":"Mitchell","sequence":"first","affiliation":[{"name":"Haematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK (CRUK) and University College London (UCL) Cancer Trials Centre, UCL Cancer Institute, UCL, London, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Barretta","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Clifton-Hadley","sequence":"additional","affiliation":[{"name":"Cancer Research UK (CRUK) and University College London (UCL) Cancer Trials Centre, UCL Cancer Institute, UCL, London, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lawrie","sequence":"additional","affiliation":[{"name":"Cancer Research UK (CRUK) and University College London (UCL) Cancer Trials Centre, UCL Cancer Institute, UCL, London, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SooWah","family":"Lee","sequence":"additional","affiliation":[{"name":"Haematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Leongamornlert","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Centre, Hinxton, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[{"name":"United Bristol Healthcare Trust, Bristol, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8737-8465","authenticated-orcid":false,"given":"Andrew K.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Centre for Clinical Haematology, Nottingham City Hospital, Nottingham, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias F.","family":"Menne","sequence":"additional","affiliation":[{"name":"Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle upon Tyne, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Patel","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, The London School of Medicine, Queen Mary University of London, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pip","family":"Patrick","sequence":"additional","affiliation":[{"name":"Cancer Research UK (CRUK) and University College London (UCL) Cancer Trials Centre, UCL Cancer Institute, UCL, London, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Rowntree","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board (UHB), Wales, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Zareian","sequence":"additional","affiliation":[{"name":"Haematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina Zuborne","family":"Alapi","sequence":"additional","affiliation":[{"name":"Haematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Moorman","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-7789","authenticated-orcid":false,"given":"Adele K.","family":"Fielding","sequence":"additional","affiliation":[{"name":"Haematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"7191","key":"2021090315383839400_B1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature."},{"issue":"5","key":"2021090315383839400_B2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med."},{"issue":"25","key":"2021090315383839400_B3","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","article-title":"IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia","volume":"30","author":"Moorman","year":"2012","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021090315383839400_B4","first-page":"2112","article-title":"Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia","volume":"5","author":"Sun","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2021090315383839400_B5","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.1999.17.12.3753","article-title":"Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia","volume":"17","author":"Sun","year":"1999","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021090315383839400_B6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1073\/pnas.96.2.680","article-title":"Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia","volume":"96","author":"Sun","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"issue":"10","key":"2021090315383839400_B7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3324\/haematol.2016.161273","article-title":"Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia","volume":"102","author":"Kobitzsch","year":"2017","journal-title":"Haematologica."},{"issue":"2","key":"2021090315383839400_B8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3324\/haematol.2018.196055","article-title":"Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"104","author":"Fedullo","year":"2019","journal-title":"Haematologica."},{"issue":"12","key":"2021090315383839400_B9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/gcc.20818","article-title":"Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia","volume":"49","author":"Schwab","year":"2010","journal-title":"Genes Chromosomes Cancer."},{"issue":"4","key":"2021090315383839400_B10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2012.073965","article-title":"Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia","volume":"98","author":"Caye","year":"2013","journal-title":"Haematologica."},{"issue":"3","key":"2021090315383839400_B11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","volume":"24","author":"Br\u00fcggemann","year":"2010","journal-title":"Leukemia."},{"issue":"1","key":"2021090315383839400_B12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia."},{"issue":"11","key":"2021090315383839400_B13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2021090315383839400_B14","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41598-019-41078-4","article-title":"Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"9","author":"Steeghs","year":"2019","journal-title":"Sci Rep."},{"issue":"24","key":"2021090315383839400_B15","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood."},{"issue":"12","key":"2021090315383839400_B16","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3322\/1821096\/advancesadv2021004430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3322\/1821096\/advancesadv2021004430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:54:34Z","timestamp":1630670074000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/17\/3322\/476674\/IKZF1-alterations-are-not-associated-with-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":16,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004430","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}